Clinical trial
Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary…
NCT00133003 · Deutsches Herzzentrum Muenchen, Other · Completed
Key facts
| NCT number | NCT00133003 |
|---|---|
| Title | Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2) |
| Official title | Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of the Glycoprotein IIb/IIIa Inhibition With Abciximab in Patients With ACS Undergoing Coronary Stenting After Pretreatment With a High Loading Dose of Clopidogrel (ISAR-REACT-2) |
| Lead sponsor | Deutsches Herzzentrum Muenchen, Other |
| Collaborators | Technical University of Munich |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Coronary Disease, Angina, Unstable |
| Intervention type | Drug |
| Interventions | Abciximab, Placebo |
| Enrollment | 2,022 |
| Start date | Mar 1, 2003 |
| Primary completion | Jan 1, 2006 |
| Completion | Jan 1, 2006 |
| First posted | Aug 22, 2005 |
| Last update posted | Apr 15, 2008 |
| Countries | Brazil, Germany, Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: